Carboplatin and Etoposide (lung) - SWAG Cancer Alliance

The North London Cancer Network. Dose adjustments in renal impairment. January 2009. Written/reviewed by: Dr A Dangoor (Consultant Oncologist, UHBristol NHS Trust), Dr P Jankowska (Consultant Oncologist, Taunton and Somerset NHS Trust) Checked by: Sarah Murdoch (Senior Oncology Pharmacist, SW Strategic Clinical Network), Kate Gregory (Lead

  London, Alliance, Cancer, London cancer, Cancer alliance

Cetuximab and Encorafenib - SWAG Cancer Alliance

Version 1 Review date Jan 2024 Page 4 of 8 Interrupt cetuximab and/or encorafenib in severe skin reactions (grade 3 acneiform rash). Cetuximab may only be

Daratumumab, bortezomib & dexamethasone (DVd)

Subcutaneous daratumumab Administer via sub-cutaneous injection over 5 minutes. Patients should be observed for at least 6 hours after the end of the SC injection following the first dose (or as per local policy) and, if deemed necessary, after subsequent injections. Pre-medication 1-3 hours prior to daratumumab infusion (or subcutaneous ...

  Medication, Daratumumab

Quick Reference Guide - MRSA Topical Eradication

Extravasation Oxaliplatin is an exfoliant (Group 4). ... management and prognosis is not particularly strong. Coronary artery spasm is more common in patients receiving continuous infusions of fluorouracil, and is usually ... Quick Reference Guide - …

  Guide, Management, Extravasation

Trastuzumab emtansine – Kadcyla®

Drug Induced Liver Injury (DILI) Serum transaminases > 3 x ULN and concomitant total bilirubin > 2× ULN Permanently discontinue Kadcyla in the absence of another likely cause for the elevation of liver enzymes and bilirubin, e.g. liver metastasis or concomitant medication

  Induced

BEP 500 (Bleomycin, Etoposide and Cisplatin)

Version 2 Review date December 2021 Page 1 of 6 _____ Indication First line chemotherapy for good prognosis metastatic germ cell cancer (non-seminoma, combined or seminoma) – 3 cycles. First line chemotherapy for intermediate/poor prognosis metastatic germ cell cancer – 4 cycles (the 5-day schedule is usually preferred for this group). ICD ...

  Review, Cancer

FOLFIRI - Irinotecan and Modified de Gramont Fluorouracil ...

Warfarin/coumarin anticoagulants: Avoid use due to elevations in INR. Switch to low molecular weight heparin during treatment. Irinotecan: Irinotecan is a major substrate of cytochrome P450 CYP2B6 and CYP3A4 and as such levels of irinotecan may be reduced by medicines that induce levels of these enzymes.

  Coumarin

BC Cancer Protocol Summary for Treatment of Philadelphia ...

Adult patients with Ph-positive or Ph-negative pre-B cell acute lymphoblastic leukemia (ALL) Relapsed or refractory after at least oneof the followings: Refractory to induction or to salvage chemotherapy Relapse within 12 months of first remission (CR1)

  Negative, Refractory, Relapsed, Negative pre

NSSG Chemotherapy Protocol - NSSG - Haematology

Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative TREATMENT INTENT Disease modification PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record stage and IPI of disease - CT scan (neck, chest, abdomen and pelvis), and/or ...

  Negative, Refractory, Relapsed

HIGHLIGHTS OF PRESCRIBING INFORMATION These …

Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (1.3) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. (1.4)

  Information, Prescribing, Prescribing information, Refractory, Relapsed

Keytruda - Europa

negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD L1 with a CPS ≥ 10, based on the results from the pivotal KEYNOTE-590 (KN590) trial. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Minor updates are also included in Annex

  Negative